Ignite Creation Date:
2024-05-06 @ 12:55 PM
Last Modification Date:
2024-10-26 @ 1:06 PM
Study NCT ID:
NCT03889626
Status:
UNKNOWN
Last Update Posted:
2019-03-26
First Post:
2019-03-17
Brief Title:
The Maintenance Treatment of ApatinibCapecitabine Versus Observation in Advanced Gastric Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Phase III Study of Comparing the Maintenance Treatment of Apatinib Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer
Status:
UNKNOWN
Status Verified Date:
2019-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of ApatinibCapecitabine after fluorouracil and platinum based first-line chemotherapy in advanced gastric cancer
Detailed Description:
Up to now whether maintenance therapy after first line treatment can bring survival benefits to patients with advanced gastric cancer is unknown and let alone which drug is most suitable Our study is designed to prove whether the maintenance treatment of Apatinib or Capecitabine are better than observation after fluorouracilplatinum based first-line chemotherapy in advanced gastric cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None